Colossal Biosciences: Valuation, Funding & Investors
Colossal Biosciences is a pioneering company in the field of de-extinction, focusing on avian cellular science and biodiversity conservation. The company is advancing efforts to revive extinct species, such as the dodo, through breakthroughs in gene editing and primordial germ cell culture. By developing innovative genomic resources and establishing breeding colonies, Colossal aims to facilitate conservation and rewilding initiatives, while also expanding the possibilities for genetic rescue of endangered bird species.
Leadership & Board
Key Executives
- Co-Founder and CEO
- Ben Lamm
- Co-Founder & Chief Business Officer
- Peter Phillips
- Co-Founder + COO
- Kent Wakeford
- VP of Strategy
- Alexander Titus
- Current Number of Employees
- 266
- Current LinkedIn Followers
- 58,816
Latest Estimated Valuation
- Estimated Valuation
- $10B
- Total Amount Raised
- $120M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $120M
- Latest Funding Round
- Series C
- Post-Money Valuation
- $10B
Employee Trend
Colossal Biosciences had 266 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Colossal Biosciences had 58,816 followers as of November 9, 2026. The number of followers increased by 212 (0.36%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 17, 2025 | Series C | $120.00M | $10.32B |
Investors
| Investor Name | Funding Round |
|---|---|
| USIT | Series C |
| Bob Nelsen | Series C |
| Peter Jackson | Series C |
Similar Companies
A snapshot of private companies similar to Colossal Biosciences, helping you discover and navigate related company profiles.
Related News and Analysis
